Latest News

New publication in BJC on multi-cancer early detection genomic blood test

A recent article by EpidStrategies scientists Dr. Sarah Cohen and Ms. Heidi Reichert, with co-authors from academia and industry, examines a new type of cancer screening that portends a potential paradigm shift in detecting multiple forms of cancer with a single blood test. Multi-cancer early detection (MCED) tests have the potential to greatly improve screening efficacy, to lower the overall cost of follow-up testing by reducing the number of false positives, and to provide early detection of more than 50 types of cancer, many of which have no currently recommended screening tests. This publication demonstrates that MCED test technology added to current cancer screening guidelines may greatly increase the number of cancers detected without a large increase in false positives—all at a relatively low cost per cancer diagnosed. The British Journal of Cancer has made the paper available via open access, along with a corresponding blog piece by the first author, Dr. Allan Hackshaw, of University College London.